Akero Therapeutics Inc’s recently made public that its Chief Development Officer Yale Catriona unloaded Company’s shares for reported $0.45 million on Mar 17 ’25. In the deal valued at $44.76 per share,10,000 shares were sold. As a result of this transaction, Yale Catriona now holds 95,034 shares worth roughly $4.28 million.
Then, Cheng Andrew sold 1,738 shares, generating $78,001 in total proceeds. Upon selling the shares at $44.88, the President and CEO now owns 654,324 shares.
Before that, Young Jonathan sold 607 shares. Akero Therapeutics Inc shares valued at $27,242 were divested by the Chief Operating Officer at a price of $44.88 per share. As a result of the transaction, Young Jonathan now holds 200,540 shares, worth roughly $9.04 million.
BofA Securities upgraded its Akero Therapeutics Inc [AKRO] rating to a Buy from a a Neutral in a research note published on January 30, 2025; the price target was increased to $63 from $35. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in late January has reiterated a ‘”a Buy”‘ rating for it. Citigroup began covering AKRO with “Buy” recommendation on November 18, 2024.
Price Performance Review of AKRO
On Monday, Akero Therapeutics Inc [NASDAQ:AKRO] saw its stock fall -0.31% to $45.08. Over the last five days, the stock has gained 0.58%. Akero Therapeutics Inc shares have risen nearly 62.04% since the year began. Nevertheless, the stocks have risen 78.96% over the past one year. While a 52-week high of $58.40 was reached on 01/27/25, a 52-week low of $17.86 was recorded on 01/14/25. SMA at 50 days reached $43.82, while 200 days put it at $31.63.
Levels Of Support And Resistance For AKRO Stock
The 24-hour chart illustrates a support level at 44.41, which if violated will result in even more drops to 43.75. On the upside, there is a resistance level at 45.94. A further resistance level may holdings at 46.81. The Relative Strength Index (RSI) on the 14-day chart is 50.04, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.75, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 34.06%. Stochastics %K at 60.08% indicates the stock is a holding.
How much short interest is there in Akero Therapeutics Inc?
A steep rise in short interest was recorded in Akero Therapeutics Inc stocks on 2025-02-28, growing by 1.42 million shares to a total of 5.05 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 3.63 million shares. There was a rise of 28.19%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 19, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $69 price target.
